http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109096136-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C229-64
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C227-40
filingDate 2018-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-109096136-B
titleOfInvention Erlotinib intermediate compound and refining method thereof
abstract The invention relates to an erlotinib intermediate compound and a refining method thereof, belonging to the technical field of medicines. The erlotinib intermediate compound is 2-amino-4, 5-di (2-methoxyethoxy) ethyl benzoate hydrochloride. The refining method comprises 5 steps: 1. dissolving the intermediate compound crude product in water, adding alumina for adsorption after dissolving, and filtering to remove the alumina; 2. adding isopropyl acetate into the filtrate obtained in the step 1, adding solid alkali to adjust the pH value to 7-8, stirring, standing, and layering; 3. adding the organic phase obtained in the step 2 into active carbon for decoloring, precisely filtering the active carbon, and evaporating part of isopropyl acetate under reduced pressure; 4. adding methanol into the distillation residual liquid in the step 3, dropwise adding thionyl chloride, stopping dropwise adding when the pH value is detected to be qualified, and continuously stirring; 5. and (4) cooling, then carrying out suction filtration, leaching the organic solvent, and drying to obtain a target product. The refining method is scientific and reasonable, has high recovery rate and is easy for industrial production.
priorityDate 2018-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104193688-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108358798-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104725327-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537701
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393705
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408978442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10480
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3587356
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9989226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451818717
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453034310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419489307
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70700640
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451867047
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451829787
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419539429
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516892
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176870
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407319186
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24386
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6569
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559581
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID297
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419525298
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7967
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23696331
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448306520

Total number of triples: 43.